EBITDA for Insmed (INSM)
According to Insmed's latest reported financial statements, the company's current EBITDA (TTM) is -$1.18B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
INSM
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
-$1.18B
YoY change
+43.1%
5Y CAGR
N/A
Peak year (2009)
$120.31M
Cumulative EBITDA
-$5.09B
EBITDA history chart for Insmed (INSM) from 1999 to 2025
EBITDA history table for Insmed (INSM) from 1999 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | -$1.17B | +43.1% | ||
| 2024 | -$818.79M | +24.0% | ||
| 2023 | -$660.18M | +47.6% | ||
| 2022 | -$447.37M | +16.6% | ||
| 2021 | -$383.65M | +53.2% | ||
| 2020 | -$250.37M | +15.3% | ||
| 2019 | -$217.07M | -26.5% | ||
| 2018 | -$295.18M | +60.3% | ||
| 2017 | -$184.09M | +8.1% | ||
| 2016 | -$170.24M | +47.7% | ||
| 2015 | -$115.28M | +33.9% | ||
| 2014 | -$86.09M | +58.8% | ||
| 2013 | -$54.20M | +35.3% | ||
| 2012 | -$40.05M | -32.5% | ||
| 2011 | -$59.31M | +857.7% | ||
| 2010 | -$6.19M | -105.1% | ||
| 2009 | $120.31M | -1000.0% | ||
| 2008 | -$13.37M | -33.3% | ||
| 2007 | -$20.03M | -60.7% | ||
| 2006 | -$51.00M | +250.9% | ||
| 2005 | -$14.54M | -46.9% | ||
| 2004 | -$27.39M | +161.1% | ||
| 2003 | -$10.49M | -69.3% | ||
| 2002 | -$34.15M | -11.6% | ||
| 2001 | -$38.64M | +27.5% | ||
| 2000 | -$30.31M | +276.9% | ||
| 1999 | -$8.04M | — |
EBITDA values are taken from Insmed's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual EBITDA for Insmed (INSM) came in at -$1.17B – surged 43.1% year-over-year.
Between 2009 and 2025, Insmed EBITDA plunged 1073.7%, falling from $120.31M to -$1.17B.
Across the available history, EBITDA reached its high of $120.31M in 2009 and its low of -$1.17B in 2025.
Among 8 Healthcare peers, Insmed (INSM) ranks 9th; the peer median for EBITDA is $24.21B.
Insmed EBITDA by Year
Insmed EBITDA 2025: -$1.17B
Insmed EBITDA in 2025 was -$1.17B, surged 43.1% from 2024. This figure represents the lowest annual value in the available history.
Insmed EBITDA 2024: -$818.79M
Insmed EBITDA in 2024 was -$818.79M, grew 24.0% from 2023.
Insmed EBITDA 2023: -$660.18M
Insmed EBITDA in 2023 was -$660.18M, surged 47.6% from 2022.
Insmed EBITDA 2022: -$447.37M
Insmed EBITDA in 2022 was -$447.37M, grew 16.6% from 2021.
Insmed EBITDA 2021: -$383.65M
Insmed EBITDA in 2021 was -$383.65M.
See more financial history for Insmed (INSM).
Sector peers — EBITDA
Companies in the same sector as Insmed, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Insmed's EBITDA?
- Latest reported EBITDA for Insmed (INSM) is -$1.18B (period ending December 31, 2025).
How has Insmed EBITDA changed year-over-year?
- Insmed (INSM) EBITDA changed +43.1% year-over-year on the latest annual filing.
When did Insmed EBITDA hit its highest annual value?
- Insmed EBITDA reached its highest annual value of $120.31M in 2009.
What was Insmed EBITDA in 2024?
- Insmed (INSM) EBITDA in 2024 was -$818.79M.
What was Insmed EBITDA in 2025?
- Insmed (INSM) EBITDA in 2025 was -$1.17B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
INSM Overview
Company profile, financial tools, and key metrics
INSM Revenue Counter
Earns $19.23 every second. See per minute, hour, and day.
INSM Earnings Counter
Loses −$40.49 per second. See per minute, hour, and day.
INSM Economic Scale
Exceeds Micronesia, Fed. Sts.'s GDP. Compare with world economies.
INSM What If Invested
What if you had invested $1,000? See historical returns from any date.
INSM How It Makes Money
Discover visual breakdown of $606.42M in revenue — where it comes from and where it goes.
INSM Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
INSM Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
INSM Daily Price Character
Explosive · 46.7% historical win rate (green days). Streaks & record days.
INSM Buybacks
See repurchase history & metrics. Shareholder yield & SBC comparison.
INSM Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.